IP Library Granted Patent US 8,633,305
Granted Patent B2
US 8,633,305 · App. 13/297,095 · Granted Jan 21, 2014

Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules

Inventor: Leland Shapiro (Denver, CO)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,633,305
App. No.
13/297,095
Granted
Jan 21, 2014
Kind
B2
Abstract

A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine.

Claims (21)

1. A construct comprising a nucleic acid sequence encoding a fusion polypeptide comprising:

a first nucleic acid encoding mammalian alpha-1 antitrypsin (AAT); and

a second nucleic acid encoding an IgG1 Fc.

2. The construct of claim 1 , wherein the mammalian alpha-1 antitrypsin (AAT) comprises naturally occurring human alpha-1 antitrypsin (AAT).

3. The construct of claim 1 , wherein the construct comprises an M-type AAT.

4. The construct of claim 1 , wherein the construct comprises a fusion protein wherein mammalian alpha-1 antitrypsin (AAT) is fused to the amino-terminus or carboxy-terminus of Fc.

5. The construct of claim 1 , wherein the encoded fusion polypeptide is part of a pharmaceutical composition that further comprises a pharmaceutically acceptable carrier or excipient.

6. The construct of claim 1 , wherein the first nucleic acid sequence comprises SEQ ID NO: 68 or SEQ ID NO:78.

7. The construct of claim 1 , wherein the nucleic acid sequence encoding the fusion polypeptide is SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74; SEQ ID NO: 80, SEQ ID NO: 82, or SEQ ID NO:84.

8. A vector comprising the nucleic acid construct of claim 1 .

9. An expression vector comprising the nucleic acid construct of claim 1 and a promoter operatively linked thereto.

10. A transformed cell comprising the vector of claim 8 .

11. An isolated preparation of expressed inclusion bodies comprising an encoded fusion polypeptide of the construct of claim 1 .

12. The expression vector of claim 9 , comprising:

1) a nucleic acid sequence encoding the fusion polypeptide of SEQ ID NO: 71;

2) a nucleic acid sequence encoding the fusion polypeptide of SEQ ID NO: 73;

3) a nucleic acid sequence encoding the fusion polypeptide of SEQ ID NO: 75;

4) a nucleic acid sequence encoding the fusion polypeptide of SEQ ID NO: 81;

5) a nucleic acid sequence encoding the fusion polypeptide of SEQ ID NO: 83; or

6) a nucleic acid sequence encoding the fusion polypeptide of SEQ ID NO: 85;

wherein the construct encodes mammalian alpha-1 antitrypsin (AAT) fused to an IgG1 Fc.

Continuity (4)
Continuation 12555895 · Sep 9, 2009
Division 10926051 · Aug 26, 2004
Provisional Application 60497703 · Aug 26, 2003
Related Publication 20120071545A1 · Mar 22, 2012